Formycon Points To Positive Results For Keytruda Biosimilar

Pembrolizumab Candidate Is ‘Structurally And Functionally Highly Similar’ To Brand

 
• By Dave Wallace
  
Formycon has championed study results for its Keytruda biosimilar (Shutterstock)

More from Biosimilars

More from Generics Bulletin